Carrie Baker Brachmann
YOU?
Author Swipe
View article: RNA-seq RNAaccess identified as the preferred method for gene expression analysis of low quality FFPE samples
RNA-seq RNAaccess identified as the preferred method for gene expression analysis of low quality FFPE samples Open
Clinical tumor tissues that are preserved as formalin-fixed paraffin-embedded (FFPE) samples result in extensive cross-linking, fragmentation, and chemical modification of RNA, posing significant challenges for RNA-seq-based gene expressio…
View article: Table S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S2. Baseline Characteristics in the Tumor SPARC-Evaluable Population
View article: Supplementary Figure 3 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Supplementary Figure 3 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Free (red) and total (blue) MMP9 for each patient in the monotherapy cohorts at Day 15 and Day 43 or End of Study (Days 40-57). Individual patients are separated by light gray dashed lines and dose groups by black dashed lines. The horizon…
View article: supplemental figure legend from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
supplemental figure legend from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
supplemental figure legend
View article: Table S5 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S5 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S5. Changes in Plasma SPARC From Baseline to Cycles 2 and 4
View article: Supplementary Figure 3 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Supplementary Figure 3 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Free (red) and total (blue) MMP9 for each patient in the monotherapy cohorts at Day 15 and Day 43 or End of Study (Days 40-57). Individual patients are separated by light gray dashed lines and dose groups by black dashed lines. The horizon…
View article: Figure S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Figure S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Figure S2. Correlation of Baseline Plasma SPARC with Stromal SPARC. In total, 218 of 256 in the SPARC IHC evaluable group had baseline plasma values. No correlation was observed between baseline plasma SPARC and stromal SPARC.
View article: Supplementary Figure 2 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Supplementary Figure 2 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Efficacy summary for patients with gastric/GEJ adenocarcinoma (Part B).
View article: Supplementary Figure 1 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Supplementary Figure 1 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Full study schema (ClinicalTrials.gov Identifier: NCT01803282)
View article: Supplementary Figure 2 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Supplementary Figure 2 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Efficacy summary for patients with gastric/GEJ adenocarcinoma (Part B).
View article: Supplementary Figure 1 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Supplementary Figure 1 from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Full study schema (ClinicalTrials.gov Identifier: NCT01803282)
View article: Data from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Data from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Purpose: nab-Paclitaxel plus gemcitabine was superior to gemcitabine alone for patients with metastatic pancreatic cancer (MPC) in the phase III MPACT trial. This study evaluated the association of secreted protein acidic and rich in cyste…
View article: Data from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Data from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Purpose: nab-Paclitaxel plus gemcitabine was superior to gemcitabine alone for patients with metastatic pancreatic cancer (MPC) in the phase III MPACT trial. This study evaluated the association of secreted protein acidic and rich in cyste…
View article: Figure S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Figure S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Figure S1 . Representative SPARC staining. (A) Representative SPARC staining in stroma. (B) Representative SPARC staining in tumor epithelia.
View article: Table S3 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S3 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S3. Baseline Characteristics in the Plasma SPARC-Evaluable Population
View article: Table S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S2. Baseline Characteristics in the Tumor SPARC-Evaluable Population
View article: Table S4 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S4 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S4. Baseline Values in the Plasma SPARC-Evaluable Population
View article: Supplementary Material from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Supplementary Material from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Method for Free and Total MMP9 assays
View article: Table S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S1. Baseline Characteristics in the Stromal SPARC-Evaluable Population
View article: Table S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S1. Baseline Characteristics in the Stromal SPARC-Evaluable Population
View article: Table S4 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S4 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S4. Baseline Values in the Plasma SPARC-Evaluable Population
View article: Table S3 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S3 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S3. Baseline Characteristics in the Plasma SPARC-Evaluable Population
View article: supplemental figure legend from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
supplemental figure legend from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
supplemental figure legend
View article: Figure S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Figure S2 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Figure S2. Correlation of Baseline Plasma SPARC with Stromal SPARC. In total, 218 of 256 in the SPARC IHC evaluable group had baseline plasma values. No correlation was observed between baseline plasma SPARC and stromal SPARC.
View article: Supplementary Material from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Supplementary Material from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Method for Free and Total MMP9 assays
View article: Data from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Data from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Purpose: Matrix metalloproteinase-9 (MMP9) is implicated in protumorigenic processes. Andecaliximab (GS-5745, a monoclonal antibody targeting MMP9) was evaluated as monotherapy and in combination with mFOLFOX6.Patients and Methods: Three d…
View article: Table S5 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Table S5 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Table S5. Changes in Plasma SPARC From Baseline to Cycles 2 and 4
View article: Figure S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial
Figure S1 from SPARC Expression Did Not Predict Efficacy of <i>nab</i>-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial Open
Figure S1 . Representative SPARC staining. (A) Representative SPARC staining in stroma. (B) Representative SPARC staining in tumor epithelia.
View article: Data from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study
Data from Andecaliximab/GS-5745 Alone and Combined with mFOLFOX6 in Advanced Gastric and Gastroesophageal Junction Adenocarcinoma: Results from a Phase I Study Open
Purpose: Matrix metalloproteinase-9 (MMP9) is implicated in protumorigenic processes. Andecaliximab (GS-5745, a monoclonal antibody targeting MMP9) was evaluated as monotherapy and in combination with mFOLFOX6.Patients and Methods: Three d…
View article: Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival
Randomized, open-label, phase 2 study of andecaliximab plus nivolumab versus nivolumab alone in advanced gastric cancer identifies biomarkers associated with survival Open
Background Matrix metalloproteinase-9 (MMP9) selectively cleaves extracellular matrix proteins contributing to tumor growth and an immunosuppressive microenvironment. This study evaluated andecaliximab (ADX), an inhibitor of MMP9, in combi…